Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed non-Hodgkin's lymphoma * Working formulation low-, intermediate-, and high-grade histologies eligible * Mantle cell and marginal zone lymphoma eligible * Relapse after at least 1 doxorubicin-containing regimen required * No more than 2 prior chemotherapy regimens * One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed * No prior bone marrow transplantation * Ineligible for treatment on higher priority protocols * Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk * Bidimensionally measurable disease required * No history of primary or metastatic CNS disease PATIENT CHARACTERISTICS: * Age: Any age * Performance status: Zubrod 0-2 * Life expectancy: Greater than 12 weeks * Absolute neutrophil count at least 1,000/mm3 * Platelet count at least 100,000/mm3 * Bilirubin no greater than 1.8 mg/dL * Transaminases no greater than 2.5 times normal * Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min * No HIV antibody * No serious intercurrent illness * No pregnant or nursing women * Effective contraception required of fertile patients throughout study and for 1 year thereafter PRIOR CONCURRENT THERAPY: -At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered